BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Sustained virologic response
1
Direct-acting antiviral therapy reduces variceal rebleeding and improves liver function in hepatitis C virus-related cirrhosis: A multicenter retrospective cohort study
11/27/2025 7:53:58 AM | Browse: 73 | Download: 362
2
Gender disparities in hepatitis C treatment: A call for tailored approaches
9/25/2025 11:24:00 AM | Browse: 101 | Download: 249
3
Shear-wave elastography to predict hepatocellular carcinoma after hepatitis C virus eradication: A systematic review and meta-analysis
3/14/2024 5:31:17 PM | Browse: 301 | Download: 1207
4
Stages of care for patients with chronic hepatitis C at a hospital in southern Brazil
8/22/2023 7:39:26 AM | Browse: 467 | Download: 1537
5
Effectiveness and safety of generic and brand direct acting antivirals for the treatment of chronic hepatitis C
12/2/2022 12:50:19 PM | Browse: 618 | Download: 1891
6
Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients
12/2/2022 9:49:51 AM | Browse: 668 | Download: 1728
7
Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study
8/10/2022 8:23:14 AM | Browse: 699 | Download: 2266
8
Hepatitis C virus burden: Treating and educating people without prejudice
7/27/2022 1:17:38 PM | Browse: 698 | Download: 2091
9
Benign course of residual inflammation at end of treatment of liver transplant recipients after sofosbuvir based therapy
3/24/2022 2:13:21 PM | Browse: 707 | Download: 2201
10
Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections
3/17/2022 3:25:03 AM | Browse: 629 | Download: 1824
11
Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate
2/23/2022 3:51:55 PM | Browse: 653 | Download: 2011
12
Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil
1/21/2022 8:16:14 AM | Browse: 747 | Download: 1937
13
Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication
12/31/2021 12:21:18 PM | Browse: 923 | Download: 2697
14
Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long?
10/27/2021 7:14:11 AM | Browse: 896 | Download: 1761
15
Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan
9/29/2021 11:12:00 AM | Browse: 644 | Download: 2072
16
Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study
5/10/2021 7:46:10 AM | Browse: 725 | Download: 2060
17
Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond
4/29/2021 2:12:02 AM | Browse: 802 | Download: 1799
18
M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals
6/6/2020 2:43:56 PM | Browse: 1496 | Download: 3245
19
Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study
10/28/2019 11:23:12 AM | Browse: 1308 | Download: 3051
20
Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions
8/7/2019 7:09:17 AM | Browse: 1361 | Download: 2490
21
Hepatitis C virus cure with direct-acting antivirals: Clinical, economic, societal and patient value for China
5/27/2019 8:24:36 AM | Browse: 1338 | Download: 2532
22
Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response
12/27/2018 9:28:07 AM | Browse: 1328 | Download: 1860
23
Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection
4/13/2017 3:45:15 PM | Browse: 1520 | Download: 3076
24
Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country
11/18/2016 3:13:00 PM | Browse: 1329 | Download: 2929
25
Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia
2/22/2016 3:38:00 PM | Browse: 1579 | Download: 3214
26
Treatment strategies for chronic hepatitis C prior to and following liver transplantation
1/7/2016 12:14:00 PM | Browse: 1356 | Download: 2140
27
Update on hepatitis C: Direct-acting antivirals
12/4/2015 3:24:00 PM | Browse: 1372 | Download: 2438
28
Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?
8/13/2015 10:30:00 AM | Browse: 1481 | Download: 2347
29
Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients
8/8/2015 3:25:00 PM | Browse: 1379 | Download: 3044
30
Predictive factors associated with hepatitis C antiviral therapy response
6/29/2015 5:40:00 PM | Browse: 1423 | Download: 2494
31
Interferon-3 polymorphisms in pegylated-interferon- plus ribavirin therapy for genotype-2 chronic hepatitis C
4/7/2015 6:08:00 PM | Browse: 1215 | Download: 2328
32
Sofosbuvir and ABT-450: Terminator of hepatitis C virus?
9/16/2014 9:54:00 AM | Browse: 1653 | Download: 1755
Write to the Help Desk
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.